Ligand-based drug design considering specific features of aldose reductase  thumbnail
Pause
Mute
Subtitles not available
Playback speed
0.25
0.5
0.75
1
1.25
1.5
1.75
2
Full screen

Ligand-based drug design considering specific features of aldose reductase

Published on Jul 09, 2018394 Views

Aldose reductase is as a rate-limiting enzyme in the polyol pathway, one of the main mechanisms of glucose toxicity. Inhibitors of aldose reductase showed to be helpful in prevention of diabetic compl

Related categories

Chapter list

Ligand-based drug design considering specific features of aldose reductase00:00
Department of Biochemical Pharmacology00:22
G-LUCK - Pharmacological intervention in glucose-toxicity in type 2 diabetes01:07
Aldo-keto reductases02:07
Late (chronic) diabetic complications 03:02
Patients with T2DM – insulin resistance03:46
Polyol pathway05:06
ALR2 - 105:31
ALR2 - 206:37
MEP dependance on pH08:05
MEP of aldose reductase - 108:56
MEP of aldose reductase - 209:12
2 substrates mechanism10:22
Inhibitors12:12
Safety belt13:39
History13:55
Hexahydropyridoindoles – efficient radical scavengers - 114:05
Hexahydropyridoindoles – efficient radical scavengers - 214:35
Carboxymethylated pyridoindoles14:55
3-D structure15:09
basic (protonated) nitrogen + acidic (dissociated) >COO- => zwitterion15:12
tetrahydropyridoindoles16:02
Indole acetic acids 16:26
Database of indole derivatives for in silico ADMET and activity study16:43
methylation at R2 and R316:53
tricyclic structure of cemtirestat - 117:09
tricyclic structure of cemtirestat - 217:23
Rat ALR2 - 117:47
Rat ALR2 - 218:05
Rat ALR2 - 319:13
Rat ALR2 - 419:15
Rat ALR2 - 519:32
2nd substrate-protein-cofactor 19:46
Software20:05
Acknowledgements:20:11
Funding20:43